FDA Approves NINTEDANIB — Glenmark Pharmaceuticals Inc., USA
Glenmark Pharmaceuticals Inc. received regulatory clearance on July 9, 2026, for the approved ANDA212555, positioning the company to enter the market for the oral nintedanib esylat…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Glenmark Pharmaceuticals Inc. received regulatory clearance on July 9, 2026, for the approved ANDA212555, positioning the company to enter the market for the oral nintedanib esylat…
Sanofi-Aventis U.S. LLC has secured FDA approval for SARCLISA ESCENA (isatuximab-irfc), the subcutaneous formulation of the multiple-myeloma therapy. This development enhances the …
ASPIRO announced receipt of FDA approval for a new generic drug, signaling potential immediate market penetration in the sector following the decision.
Macleods Pharmaceuticals Limited (Macleods) has received FDA approval for the ANDA for DAPSONE, ensuring continued access to this essential medication for treating leprosy. The app…
Baxter Healthcare Corporation received FDA approval for Intravenous Ephedrine Sulfate (ANDA216740) on July 8, 2026, entering a market poised for potential price volatility as the p…
QUAGEN has received federal approval for ANDA213892, likely allowing the company to introduce a generic version of the recently approved July 7th product. This expansion of the com…
Renova Pharmaceuticals LLC announced today that the FDA has approved intravesical dimethyl sulfoxide for medical use, a formulation that may enter a niche market for managing pain …
Vera Therapeutics, Inc. announced the FDA approval of atacicept (TRUTAKNA), positioning the injectable therapy to disrupt the treatment landscape for patients with generalized myas…
Milla Pharmaceuticals received FDA approval for its Intravenous Sodium Bicarbonate (ANDA219089) on July 6, 2026, establishing a new generic option for this essential fluid-moving a…
Baxter Healthcare Corporation has received FDA approval for the intravenous formulation of levcarnitine under ANDA217896, advancing the company’s generic pipeline. The approval pro…
SABA ILAC SANAYIVE has secured FDA approval for ANDA 217934, a milestone that is expected to expand the manufacturer's commercial portfolio and provide a solid foundation for futur…
MANKIND PHARMA received FDA approval for its ANDA 220874 on July 1, 2026, according to a notice issued by the regulatory body. This clearance is expected to deliver a significant c…
Macleods Pharmaceuticals Limited and Hikma Pharmaceuticals received FDA approval for their generic chlorthalidone ANDA on July 1, 2026, which is expected to assert significant mark…
On July 1, 2026, ScieGen Pharmaceuticals received FDA approval of Brivaracetam (ANDA219952), a generic oral version of the brand-name drug. This approval will likely impact the com…
I3 PHARMS announced today the FDA approval of **[Insert Substance Name Here]** under ANDA 219464, signaling a strategic entry into the market with the potential to capitalize on co…
Zydus Pharmaceuticals has received FDA approval for a new generic drug, expected to significantly impact the market by providing a cost-effective alternative for patients and compe…
On June 30, 2026, Rising received FDA approval for ANDA219565, marking the launch of its newest bioequivalent product which is poised to create significant market competition and i…
APOTEX has announced the approval of its ANDA No. 213331 from the FDA, marking the launch of the generic version of the substance and signaling a new competitive entry into the mar…
MICRO LABS received FDA approval for defined generic applications in 2026 to market potential off-patent products, a move which should broaden its commercial portfolio and drive ne…
Novitium Pharma announced Friday it received FDA approval for its ANDA-219647, as the company moves to expand its generic portfolio with new product launches. This regulatory green…